Exploring the therapeutic potential of psychedelics: Fear extinction mechanisms and amygdala modulation
Thomas J. Kelly, Qing-Song Liu
Psychedelics August 9, 2024 DOI: 10.61373/pp024b.0019
Summary
AI-generated from the abstractClassical psychedelics are being studied as potential treatments for PTSD. Research in rodents shows these substances affect fear learning, recall, and extinction. The amygdala, a brain region central to fear processing, is key to these effects. Psychedelics interact with different cell types in the amygdala, and specific neural circuits may underlie their fear-suppressing effects. Because rodent and human amygdalas are functionally similar, findings from animal studies can guide clinical trials for psychedelic-assisted PTSD therapy. The authors emphasize that each psychedelic's unique pharmacology and duration of action are important factors for future research.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Key finding | Classical psychedelics suppress fear responses in rodents by interacting with specific neural circuits in the amygdala, and these preclinical insights can inform clinical trials for PTSD treatment. |
Abstract
Classical psychedelics are increasingly receiving attention as potential therapeutic agents for treating post-traumatic stress disorder (PTSD). Research has explored various classical psychedelics in the context of fear learning, recall, and extinction in rodents. We provide an overview of the reported effects of these substances on behavioral responses to learned fear. The amygdala complex, a key brain region involved in fear learning and extinction, plays a central role in these processes. We discuss how psychedelics interact with various cell types in the amygdala and propose which neural circuits may be essential for the observed fear-suppressing effects following psychedelic administration in rodents. The rodent amygdala has functional homology with the human amygdala. Thus, insights gained from preclinical studies can inform the design and implementation of clinical trials for psychedelic-assisted psychotherapy for PTSD. Finally, we stress the importance of considering compound-specific pharmacology and the acute duration of action as key factors in guiding the future direction of this field.